Oncology

Latest News

Dordaviprone is indicated for recurrent H3 K27M-mutant diffuse midline glioma, an ultra-rare, aggressive brain tumor primarily affecting children. | Image credit: wladimir1804 - stock.adobe.com

FDA Approves Dordaviprone as First and Only Treatment for Aggressive Form of Glioma

By Rose McNulty

August 6th 2025

Dordaviprone (Modeyso) is now approved to treat recurrent H3 K27M-mutant diffuse midline glioma, an ultra-rare, aggressive brain tumor primarily affecting children.

Gen Li, PhD, MBA, president and founder of Phesi

Real-World Data, Digital Patient Profiles Are Revolutionizing Trial Design, Patient Recruitment: Gen Li, PhD, MBA

By Pearl Steinzor
Gen Li, PhD, MBA

August 4th 2025

Value-based care. | Image Credit: irissca - stock.adobe.com

Legal Navigation Services Key to Addressing Disparities in Cancer Care

By Cameron Santoro

July 31st 2025

Radiotherapy can work synergistically with immunotherapy by reprogramming the tumor microenvironment. | Image credit: Crystallight-stock.adobe.com

Brain Radiotherapy Plus ICIs Boost Survival in SCLC With Brain Metastases

By Jared Kaltwasser

July 30th 2025

As SCLC continues to pose a therapeutic challenge due to rapid progression and early metastasis, the convergence of immunotherapy and precision radiation holds promise to extend survival and improve outcomes. | Image credit: mi_viri - stock.adobe.com

Chemoimmunotherapy Shows Promise for Limited-Stage SCLC in Real-World Study

By AJMC Contributor

July 29th 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

Continuing Medical Education

August 10th 2025

The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation

1 Credit / Cardiology, Neurology

August 10th 2025

Advancing Immunotherapy in Endometrial Cancer: A Managed Care Perspective on Personalized Care

1.5 Credits / Gynecologic Cancer, Health Equity, Diversity & Inclusion, Oncology, Women's Health

More News

NCCN Guidelines Become Resource Stratified for Global Use

March 13th 2015

NCCN Guidelines Become Resource Stratified for Global Use

Laura Joszt, MA

Resource constraints may confine the ability of physicians to deliver optimal cancer care to all patients across the world, which the National Comprehensive Cancer Network is acknowledging by resource stratifying its Guidelines.

Dr Peter Bach Explains Diminishing Returns in Cancer Drugs

March 13th 2015

Dr Peter Bach Explains Diminishing Returns in Cancer Drugs

While the cost of introductory cancer drugs is increasing rapidly, there has not been a commensurate increase in benefit, according to Peter Bach, MD, with Memorial Sloan Kettering Cancer Center.

March 13th 2015

NCCN Recommends Only One Test for Breast Cancer, Says Expert

According to Dr Amy Cyr from the Siteman Cancer Center at Washington University in St. Louis, Missouri, while Oncotype DX is both prognostic and predictive, none of the other tests currently available have shown both capabilities.

March 13th 2015

Low Breast Density Could Indicate Poor Prognosis, Study Suggests

The findings of this study, conducted in Finland, may prove significant for the assessment of breast cancer prognosis and treatment planning.

March 13th 2015

CDC Report Underscores Impact of Early Diagnosis and Innovation on Cancer Survival

Two out of three people with metastatic disease survive 5 years or more, the report shows. The authors hope the data can help researchers develop better cancer control programs.

20 Years of Creating and Embracing Guidelines in Cancer Care

March 13th 2015

20 Years of Creating and Embracing Guidelines in Cancer Care

Laura Joszt, MA

When the first National Comprehensive Cancer Network Guidelines were developed 20 years ago, even the participating members who were there at the beginning were skeptical they would be able to come to an agreement and build something lasting.

March 13th 2015

Geography Determines Appropriate Use of Imaging in Low-Risk Cancer Patients

The study, published in JAMA Oncology, found that low risk breast and prostate cancer patients received unnecessary imaging overall, with a higher rate observed in the North East region of the country.

March 12th 2015

ACS Study Recommends Increased Screening to Reduce Incidence of Colorectal Cancer

The study, published in the journal Cancer found that increasing screening rates to 80% by 2018 would reduce projected colorectal cancer incidence rates by 17% and mortality rates by 19% during short-term follow-up, and by 22% and 33%, respectively, during extended follow-up. Those reductions would amount to a total of 277,000 averted new cancers and 203,000 averted colorectal cancer deaths from 2013 through 2030.

Dr Robert Carlson Highlights Top NCCN Meeting Takeaway

March 12th 2015

Dr Robert Carlson Highlights Top NCCN Meeting Takeaway

The National Comprehensive Cancer Network (NCCN) Guidelines may be successful historically, but the network isn't resting on its laurels, Robert Carlson, MD, chief executive officer, said at the NCCN 20th Annual Meeting.

Transforming the NCCN Guidelines

March 12th 2015

Transforming the NCCN Guidelines

Laura Joszt, MA

During his keynote speech at the National Comprehensive Cancer Network (NCCN)'s 20th Annual Conference, Chief Executive Officer Robert Carlson, MD, spent the majority of his time discussing the NCCN Guidelines because they are the core of its services.

March 12th 2015

A New Strategy for Payers to Cover High Cost Specialty Medications?

A new analysis published by the RAND Corporation suggests strategies that the pharmaceutical industry could offer payers as they try to cover the front-loaded cost of newer breakthrough drugs.

March 12th 2015

Dietary Restrictions Could Prevent Colon Cancer

The study, published in JAMA Internal Medicine, found that while the complete absence of meat in the diet had the most impact on reducing the risk of colorectal cancer, those who added seafood to the vegetarian diet-pescovegetarians-faired better than the nonvegetarians.

March 12th 2015

Study Shows Experienced Care Facilities Improve Survival in NSCLC

The study, published in the Journal of Thoracic Oncology, found that patients treated with definitive concurrent chemotherapy and radiation therapy for stage 3 non-small cell lung cancer have longer overall survival when treated by highly experienced facilities, either academic or community cancer centers.

March 11th 2015

Myriad's Gene Panel Could Diagnose Metastatic Melanoma

The 23-gene diagnostic panel called myPath Melanoma could be used in addition to microscopy to distinguish the benign form of the disease from malignant disease.

March 11th 2015

Scientist Whose Discoveries Helped Develop Ipilimumab Among ASCO Honorees

The awards will be presented at ASCO's annual meeting to be held in Chicago in May this year.

March 11th 2015

NICE Recommends Gazyvaro for Treatment-Naive CLL Patients

The recommendation has not come easy for Roche. Back in October 2014, NICE had rejected Gazyravo based on inconsistencies in the filing, which were then addressed by the drug manufacturer. Subsequently, NICE struck a deal with Roche to provide the drug to NHS at a reduced price.

March 10th 2015

Escalating Drug Prices Not a Concern for All

While the PBM Express Scripts declared plans to bring cancer drug plans down, the drug manufacturers and investors aren't too worried about the high cost of some of the specialty drugs, according to this article in Bloomberg.

March 10th 2015

Breast Cancer Survivors Have Increased Risk of Thyroid Cancer

Laura Joszt, MA

Within 5 years of a breast cancer diagnosis, patients are at an increased risk of developing thyroid cancer, according to a new study, which was presented at the Endocrine Society's 97th annual meeting.

March 10th 2015

Study Evaluates Benefits of Cap on Prescription Drug Cost-Sharing for Patients on Exchanges

Commissioned by The Leukemia and Lymphoma Society, the results of the study help make the case for placing limits on out-of-pocket costs for patients that would relieve their financial burden without a significant impact to insurers.

March 9th 2015

Turning That Cell Phone Into a Tool for Oncology Care

Mary K. Caffrey

March 9th 2015

As Use of Diagnostics Rises, Challenges Remain in Education, Reimbursement

Mary K. Caffrey

March 9th 2015

Surveys Find Agreement in What Stakeholders Want From Cancer Care, and Oncology Medical Homes Deliver

March 9th 2015

How the ACA Is Changing Oncology Practice on the Ground

Mary K. Caffrey

March 9th 2015

Payers Seek Quality Measures That Matter to Patients, Fox Says

Mary K. Caffrey

March 9th 2015

Cost Matters to Cancer Patients, and Care Costs More in Hospitals, Panel Agrees

Mary K. Caffrey

March 9th 2015

As Cancer Becomes a Chronic Condition, Payers Shift Focus to Survivorship

March 9th 2015

ASCO's Yu Outlines How the "Changing Value Proposition" Is Redefining the Oncologist's Role

Mary K. Caffrey

March 9th 2015

Prostate Cancer in the Family Tree Increases A Woman's Risk of Breast Cancer

A study, published in the journal Cancer, found that women with a family history of both breast and prostate cancer among first-degree relatives have an almost 2-fold increase in risk of developing breast cancer themselves.

March 9th 2015

ASCO and PhRMA Critical of the CMS Oncology Care Model

One of the criticisms, which came from ASCO, points to the absence of consideration for patient heterogeneity that can result in physicians being penalized for providing patient-centered treatment.

March 9th 2015

Phase 2 Trial Defines Sunitinib Potential in Advanced Thyroid Cancer

While sunitinib failed as adjuvant treatment in advanced kidney cancer, this phase 2 study presented at the ongoing annual meeting of The Endocrine Society found that in patients with advanced thyroid cancer, sunitinib treatment resulted in median progression free survival of about 8 months. The authors think their results create sufficient evidence to initiate a phase 3 trial of the drug in thyroid cancer patients.

...

137 138 139 140 141 142 143 144 145

...

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences^® and AJMC®.
All rights reserved.

Editorial Boards

Do Not Sell My Information

Terms & Conditions